Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Delayed]RIBOMIC Announces Continued Growth in Two-Year Follow-Up of Patients Responding to Achondroplasia Treatment Drug, Umedaptanib Pegol
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30,2025(Based on Japanese GAAP)
RIBOMIC, First Half Ordinary Profit Loss Widens, Jul-Sep Ordinary Profit Loss Widens
RIBOMIC Presents Successful Phase II Clinical Trial of Achondroplasia Treatment at The Oligonucleotide Therapeutics Society International Conference
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating Clinical Proof of Concept
Announcement Regarding Discovery of Therapeutic Effects of Umedaptanib Pegol in a Diabetic Retinopathy Model and New Patent Application for Use
RIBOMIC Announces the Sustained Efficacy in a Long-Term Administration Trial of Umedaptanib Pegol for Achondroplasia
Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2025(Based on Japanese GAAP)
RIBOMIC, Apr-Jun (1Q) Ordinary Profit Loss Narrows
[Delayed]RIBOMIC Plans to Initiate PhaseIII Clinical Trial of Umedaptanib Pegol for Achondroplasia in2026 Following the Ongoing PhaseII Clinical Trial
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
RIBOMIC, The Current Fiscal Year's Net Income to Widen
Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31 2024(Based on Japanese GAAP)
RIBOMIC, Oct-Dec (3Q) Net Income Loss Widens
RIBOMIC Inc., July-September (2Q) Net Income Loss Widens
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2024(Based on Japanese GAAP)